Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. - Wikidata - wikimedia - TriplyDB

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

http://www.wikidata.org/entity/Q40524745

about

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia Interventions for treating oral candidiasis for patients with cancer receiving treatment Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Interventions for preventing oral candidiasis for patients with cancer receiving treatment Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Voriconazole versus amphotericin B in cancer patients with neutropenia Interventions for treating oral candidiasis for patients with cancer receiving treatment Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients Comparison of echinocandin antifungals Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Utilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.S Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity.Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients.Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Breakthrough invasive candidiasis in patients on micafungin.Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study Echinocandins: the newest class of antifungals.Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Canadian clinical practice guidelines for invasive candidiasis in adults.Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection Treatment options in Invasive Aspergillosis.Antifungal agents for the treatment of systemic fungal infections in children.Practice guidelines for the diagnosis and management of skin and soft-tissue infections.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Management of febrile neutropenia: ESMO Clinical Practice Guidelines.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study.

P2860

Q24200304-73856AC0-02FB-410B-820F-48DCBE95C1E0 Q24234207-A289C859-A5D0-4621-8BE0-F721D8512D72 Q24239978-18B9D256-5938-46CB-BE8F-4DE4EEA558B3 Q24243005-CA1358FA-402F-4413-B904-C883175C9386 Q24243629-ED04C08C-D6D8-4E55-9B68-E3031CDC21C5 Q24244950-3E70F11A-1521-49CA-B393-F2CF537FE376 Q24245511-F363C3B0-F8EE-4FC8-AABF-68F59DE259A3 Q25257632-086BF31B-3A53-45B1-B779-5EDD63A9A9AB Q26824260-B1F7E7E0-6364-4720-91F2-0C737A069761 Q28080147-15249D25-D795-4FC7-BE65-9FEF12440CA5 Q28273738-802E8C5B-5C89-4698-AA62-1CC538518910 Q28298468-BCFC881D-93A3-4B24-AC7B-A2584A4086AF Q28538618-47E3A0A1-7D69-4DAD-890C-3258128331E4 Q30319559-7F9AF9F1-17CB-473E-BA7A-8C741FAFCB77 Q30840066-A5493C9C-CAF8-4A10-BB01-A43C331040EC Q33234912-7F10723C-B73B-42E4-BD06-DF86927D4DDC Q33265510-1162A2B4-B5C6-490B-8E66-9D13A4A98B51 Q33723583-77D3097A-6939-4AB6-BA49-01EF60505A05 Q33876645-0BAE791F-AA26-4ABB-B0BE-FF613C2C2E97 Q33935389-ABD67E89-26F0-464F-A7F9-B4573A3528B4 Q33938068-F0DA7FA1-B165-4CFD-85CA-95D63F536C1A Q33963538-8293B00A-7849-4950-AAD0-92E0768D11A5 Q33998703-77393D46-B4E4-4FA3-AA61-080681E9E5EE Q34019188-1284DB30-0FEC-4F48-8589-96BB29673C15 Q34073422-A66C5E73-AAF3-41A7-BFC0-CBCE43A2588A Q34123805-8286FB6B-2D06-4041-8AC0-B0BAC4609972 Q34151170-1791BE34-A133-40E4-8169-CAB77408FF17 Q34237335-98AEF536-A8D5-47E2-8433-8C6D23FB0D0D Q34322081-F9341CF2-76B9-4A35-8EA1-4B7FC97F2094 Q34352014-12CF174C-FE75-4EFB-8D67-3A43CCF3241B Q34357504-9412A816-0D3E-42CC-9B97-3F1E5C9594E5 Q34437094-D6D3935C-00F0-4AD0-953F-80BF5AADB5E7 Q34460523-DB45478A-C005-4D96-8731-C1931217AD35 Q34505582-5F3D461E-C42D-4441-B618-6E11B840E9FF Q34532546-1A3C9ABA-C731-41A5-AC61-2968F88F29AC Q34546811-7CE4AD2E-19DD-48FB-8796-E81DF56DB791 Q34620670-7EEA5829-C55F-4B06-B2B5-4E33E2142F6C Q34667166-043642C9-827B-4A9F-9788-F6359643A476 Q34724824-5B6C432B-72D5-4EB7-9DAC-381BFA93AA4C Q34775518-FEEBB95E-1803-4473-898A-5AE073949B0E

P2860

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

http://www.wikidata.org/entity/Q40524745

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Caspofungin versus liposomal a ...... sistent fever and neutropenia.

@en

type

label

Caspofungin versus liposomal a ...... sistent fever and neutropenia.

@en

prefLabel

Caspofungin versus liposomal a ...... sistent fever and neutropenia.

@en

P1433

Q40524745-A08B65D4-3A6C-4722-B574-9534E3485584

P1476

Q40524745-87ABE07B-DD4D-433A-B49F-F229A916A345

P2093

Q40524745-0E222D86-78F8-4825-9B30-49BE32C8A116

Q40524745-2BC3C2A1-D8DA-4864-8BF7-2CD2A35D3033

Q40524745-3CABC3DF-4BBD-4D1B-823E-3E975E13D761

Q40524745-5B0DBE09-B6D4-4C6C-A358-7CEED6C858E1

Q40524745-651ADB98-5A47-4394-AFB1-8E55E7C470AA

Q40524745-A0D4EB45-C5DB-4B5D-B50A-F88580ADE76E

Q40524745-AA6CB697-91BC-4508-8350-0A6D9AA6D0D9

Q40524745-E4E96705-94A1-4EEC-89E3-10A8848071B4

Q40524745-E6A4F0C0-38FB-454E-B20D-4B95FE53A7A9

P304

Q40524745-64AEC689-A270-43A1-AA2E-099EA53CA1CC

P31

Q40524745-212927E7-E404-4468-B51F-606F3A69DC68

P356

Q40524745-21A275E7-723D-40E1-9D59-A88074093FC9

P407

Q40524745-355FDDCF-8CCE-4257-A26C-11F7E0F5A12C

P433

Q40524745-827F9D49-48D6-4ED7-B106-7AC6F0A5FB7A

P478

Q40524745-B77D087E-AF50-4286-92DA-62DDBF618A8E

P50

Q40524745-9B328708-BA53-415D-AB41-4D4D5B874F88

Q40524745-C0D6BC20-0560-4E66-8DF5-DB8943A04FFB

P577

Q40524745-13210821-889E-452A-A636-5AD79488B242

P698

Q40524745-A76E8DD4-C816-41D8-B351-E7BAD1898C12

P356

P1433

The New England Journal of Medicine

P1476

Caspofungin versus liposomal a ...... sistent fever and neutropenia.

@en

P2093

Ben E dePauw

http://www.w3.org/2001/XMLSchema#string

Carole A Sable

http://www.w3.org/2001/XMLSchema#string

Gerald R Donowitz

http://www.w3.org/2001/XMLSchema#string

Hedy Teppler

http://www.w3.org/2001/XMLSchema#string

Johan A Maertens

http://www.w3.org/2001/XMLSchema#string

Michael R Bourque

http://www.w3.org/2001/XMLSchema#string

Oliver A Cornely

http://www.w3.org/2001/XMLSchema#string

Robert J Lupinacci

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

P304

1391-1402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA040446

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

Anna Dmoszyńska

Lindsey R Baden

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15459300

http://www.w3.org/2001/XMLSchema#string